ClinicalTrials.Veeva

Menu

Transcutaneous Vagus Nerve Stimulation As a Pain Modulator in Knee Osteoarthritis

S

Suez Canal University

Status

Completed

Conditions

Knee Osteoarthritis

Treatments

Device: Transcutaneous Vagus Nerve Stimulation

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

a single-blinded, randomized clinical trial, 68 patients divided into 2 groups: active and sham treatment. Afferents of the Auricular branch of vagus nerve are stimulated using a transcutaneous Vagus Nerve Stimulation device (TENS 7000TM). The electrode was placed in the left cymba concha with direct contact on the skin. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 25 Hz. All participants initially will be evaluated before and after intervention and 3 months after the end of the sessions.

Full description

The included study population is 68.

  • Group (1): (tVNS group): This group of study subjects will include 34 patients of knee osteoarthritis and will be subjected to tVNS.
  • Group (2): (sham group): This group of study subjects will include 34 patients of knee osteoarthritis and will be subjected to sham treatment.

DESCRIPTION OF THE TECHNIQUE

Active treatment:

Afferents of the Auricular branch of vagus nerve were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000). The electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 10 Hz.

Sham procedure:

For sham-t-VNS device was turned 180°, stimulating the outer earlobe which does not contain fibers of the ABVN. A similar protocol as for active stimulation was used.

All participants initially will be evaluated before and after intervention and 3 months after the end of the sessions by the following:

OUTCOME MEASURES AND ASSESSMENT QUESTIONNAIRES

  1. Visual analogue scale (VAS)
  2. PainDETECT questionnaire
  3. DN4 questionnaire
  4. Radiological Imaging
  5. Knee injury and Osteoarthritis Outcome Score
  6. Hospital Anxiety Depression Scale
  7. Physical Function Tests
  8. Quantitative sensory testing
  9. The Central Sensitization Inventory

Enrollment

68 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Both genders.
  • Adult over 18 years.
  • People who were diagnosed.
  • Reported pain on visual analogue scale (VAS)>4/10.
  • Able to understand the informed consent.

Exclusion criteria

  • Peptic ulcer
  • Pace maker
  • Asthma or severe chronic obstructive pulmonary disease
  • Pregnancy.
  • Cellulites, skin ulceration at area of therapy application.
  • Inability to fulfill follow-up criteria.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

68 participants in 2 patient groups

sham Transcutaneous Vagus Nerve Stimulation
Sham Comparator group
Description:
For sham-t-VNS device was turned 180°, stimulating the outer earlobe which does not contain fibers of the ABVN. A similar protocol as for active stimulation was used.
Treatment:
Device: Transcutaneous Vagus Nerve Stimulation
Transcutaneous Vagus Nerve Stimulation
Active Comparator group
Description:
Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM) made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000). The electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 10 Hz.
Treatment:
Device: Transcutaneous Vagus Nerve Stimulation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems